Supernus Pharmaceuticals | SUPN - Umsatzkosten





Umsatzkosten Veränderung Datum
Abbott USD 5.3B 380M 2026-03
ANI Pharmaceuticals USD 114.5M 8.38M 2026-03
Aurora Cannabis CAD 88.61M 30.53M 2025-12
Bristol-Myers Squibb USD 3.86B 1.07B 2026-03
Canopy Growth CAD 53.08M 8.3M 2025-12
Cara Therapeutics USD 0 0 2025-03
Corcept Therapeutics USD 2.88M 338K 2026-03
Eisai JPY 52.02B 931M 2026-03
Eli Lilly USD 3.58B 205M 2026-03
Novo Nordisk DKK 13.6B 1.55B 2026-03
Pacira USD 50.74M 3.89M 2026-03
Perrigo USD 643.7M 103.7M 2026-03
Pfizer USD 4.59B 1.7B 2026-03
Supernus Pharmaceuticals USD 49.04M 1.5M 2026-03
United Therapeutics USD 133.4M 341.3M 2026-03
Xeris Pharmaceuticals USD 13.66M 49K 2025-12